All I Do Is Cook is on a mission to grow accessibility to Nigerian dishes. Image via allidoiscook.com

After completing the gBETA accelerator program and winning the grand prize in the ClearCo ClearPitch competition, Tobi Smith and Bethany Oyefeso are transitioning their small business, All I Do Is Cook, into a startup with the ultimate goal of making Nigerian food accessible to everybody.

Smith and Oyefeso came one step closer to that goal when Phoencia, a Houston grocery story, started stocking the startup's condiments in 2021. In that same year, Smith and Oyefesso joined the gBETA accelerator program. Smith described this program as being instrumental in the advancement of their company from a small business to a start up, now at the beginning of their pre-seed funding phase.

“They taught us everything about what it meant to be a start up and connected us with mentors and other individuals working in the food and beverage space,” says Smith.

It was during their time in the gBETA program that they learned about the ClearCo ClearPitch competition and would ultimately win the $20,000 grand prize.

“The last two years have been bonkers,” exclaims Smith, who started All I Do Is Cook as a blog in 2016, and grew it into a cooking business.

"When I arrived in Denton from Nigeria, I walked into Walmart expecting to find common Nigerian snacks but was surprised when I couldn’t find any so I started cooking my own food and sharing the recipes,” he says.

The pandemic and subsequent closing of restaurants sling-shotted them into overdrive where in just one year their number of total orders increased from 350 to over 2,000 which they then doubled in 2021 to over 4,000.

And if a focus on Nigerian food doesn’t already set them apart, their approach to production does. Smith shared that he and Oyefeso have focused heavily on the operations side of their business.

“We want everything to run as efficiently as possible with as little waste as possible,” says Smith. “We don’t carry an inventory. We only order as much produce as we need, and we only print as much packaging as we need. We know how much food we can produce in a week, and we use the timing and amount of orders as our indicator of when we might need to increase production.”

This focus on efficiency and mindfulness of the environment should keep them attractive to both investors and consumers alike.

“We are getting ready to kick off our pre-seed funding phase,” shares Smith, “and our goal is to get into the big supermarkets like Walmart, HEB, and Kroger.”

Tobi Smith and Bethany Oyefeso are taking their startup to the next level. Photos via allidoiscook.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”